Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELDORADO: Doravirine vs Dolutegravir in Treatment-naïve HIV-1 Infection
NCT06203132Phase 3Recruiting
- Sponsor
- ANRS
- Start
- Jan 2025
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of doravirine in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by ANRS. Primary endpoint: Proportion of subjects achieving HIV-1 RNA <50 copies/mL at 48 weeks. Started Jan 2025; status: recruiting.
02
Drugs
doravirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT06203132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06203132.